NRP1 and acute myeloid leukemia: Additionally, we found that the PPV of NRP‐1/CD304 for B‐ALL (79.55%) was much higher than that of BPDCN (13.64%) and AML (6.82%), and the NPV for B‐ALL reached 85.60%.